Posner Christopher 4
4 · Cara Therapeutics, Inc. · Filed Mar 4, 2024
Insider Transaction Report
Form 4
Posner Christopher
DirectorPRESIDENT AND CEO
Transactions
- Sale
Common Stock
2024-02-29$0.89/sh−5,834$5,192→ 180,521 total
Footnotes (1)
- [F1]This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on November 2, 2022 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person.